Featured Post

Wednesday Women's Health in the News: Most Frequently Asked Questions On MonaLisa Touch Vaginal Therapy

MonaLisa Touch: The Issue of Vaginal Symptoms Even with the passage of time, many women still retain their youthful energy and enthusi...

Menopause: Making Peace With Change

Wednesday, December 24, 2014

Newest Solution For the Overweight

Are you overweight? Do you have blood sugars that are abnormal? Are your lipid tests abnormal (including cholesterol)? A new year is here with a new strategy to discuss with your gyno! A new medication indication, for weight loss, has been approved by the FDA for the diabetes medication liraglutide. This drug will be marketed as Saxenda, by the company Novo Nordisk, and now will be available for your primary care gyno to pick for you for the treatment of obesity, although anticipate that it may be a bit before this is available by prescription at your local pharmacy. It is a higher dosage than is prescribed for diabetes to affect weight loss. For decades we have realized that many medications are not weight neutral, but in fact promote obesity. Newer studies have discovered that some medicaitons make lifestyle changes more effective for weight loss, and some studies indicate, even without significant lifestyle factors such as exercise and activity with the right medication women can lose weight. AS reported in Medscape recently: Liraglutide now becomes the fifth available obesity drug in the United States, after orlistat (Xenical and Alli), lorcaserin (Belviq), phentermine-topiramate (Qsymia), and bupropion/naltrexone (Contrave). Other medications, such as phentermine are also used for weight loss in selective patients. The medication liraglutide has been associated with thyroid cancer in rodents, and is not for women with multiple endocrine cancers. It has been monitored for over a decade showing there is no breast cancer risk and there is a new study that is looking at long term heart risks (hopefully lower) and long term cancer risks called the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) study, investigating the 1.8-mg dose for cardiovascular risk as well as for neoplasms and other adverse events. That study is scheduled to conclude in 2016. Although early data shows that women could lose 44% in 16 weeks, by the end of a year of medication, the average loss is about 8% due to lapses in lifestyle changes.

No comments:

Post a Comment

Thank you for your comments and questions. This blog is not intended to replace medical care, but is informational only. We hope you will become a follower or visit Womens Health Practice. We offer a variety of unique services including MonaLisa Touch, Coolsculpting, Labiaplasty, and Gynecoloigic Clinical Research Trials. For more information on menopause see http://www.amazon.com/Menopause-Make-Peace-Change

Follow on Twitter

Follow GynoGab on Twitter

Vaginal Contraceptive Ring

If you are a female between the ages of 18 and 35 you may be eligible for a contraceptive ring investigational contraceptive medication study. Qualified participants will receive study-related medical evaluations and care at no cost. If interested, please call 217-356-3736.

There was an error in this gadget

Gab ON!

Ciao, from Gyno Gab Gal! Send me questions and thoughts and let me know what is important to you! Hope to hear from you often.

Join one of our studies, become a patient at Women's Health Practice, come for an event, or visit any one of my websites our FB https://www.facebook.com/pages/Womens-Health-Practice/149858581724556?ref=hl

Women's Health Practice
Hada Cosmetic Medicine

Follow Women's Health Practice and Hada Cosmetic Medicine on Facebook https://www.facebook.com/pages/Hada-Cosmetic-Medicine/68631517372?fre!

Follow GynoGab on Twitter!

Adult Vaccination Recommendations